References
Van Gelder IC, Brügemann J, Crijns HJGM. Pharmacological management of arrhythmias in the elderly. Drugs Aging 1997; 11(2): 96–110
Packer DL, Bardy GH, Worley SJ, et al. Tachycardia-induced cardiomyopathy: a reversible form of left ventricular dysfunction. Am J Cardiol 1986; 57: 563–70
Crijns HJGM, Van Wijk LM, Van Gilst WH, et al. Acute conversion of atrial fibrillation to sinus rhythm: clinical efficacy of flecainide acetate: comparison of two regimens. Eur Heart J 1988; 9: 634–8
Suttorp MJ, Kingma HJ, Jessurun ER, et al. The value of class IC antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. J Am Coll Cardiol 1990; 16: 1722–7
Fresco C, Proclemer A, on behalf of the PAFIT-2 investigators. Management of recent onset atrial fibrillation. Eur Heart J 1996; 17 Suppl. C: 41–7
Falk RH, Knowlton AA, Bernard SA, et al. Digoxin for converting recent-onset atrial fibrillation to sinus rhythm. Ann Intern Med 1987; 106: 503–6
Salerno DM, Dias VC, Kleiger RE, et al. Efficacy and safety of intravenous diltiazem for treatment of atrial fibrillation and atrial flutter: the Diltiazem — Atrial Fibrillation/Flutter Study Group. Am J Cardiol 1989; 63: 1046–51
Van Gelder IC, Crijns HJ, Van Gilst WH, et al. Prediction of uneventful cardioversion and maintenance of sinus rhythm from direct-current electrical cardioversion of chronic atrial fibrillation and flutter. Am J Cardiol 1991; 68: 41–6
Björk U, Karesoja M, Hirvonen P. Elective cardioversion in the elderly. In: Olsson SB, Allessie MA, Campbell RWF, editors. Atrial fibrillation: mechanisms and therapeutic strategies. Armonk (NY): Futura, 1994: 343–8
Carlsson J, Tebbe U, Rox J, et al., for the ALKK-Study group. Cardioversion of atrial fibrillation in the elderly. Am J Cardiol 1996; 78: 1380–4
Van Gelder IC, Crijns HJGM, Tieleman RG, et al. Value and limitation of electrical cardioversion in patients with chronic atrial fibrillation — importance of arrhythmia risk factors and oral anticoagulation. Arch Intern Med 1996; 156: 2585–92
Cobbe SM. Using the right drug: a treatment algorithm for atrial fibrillation. Eur Heart J 1997; 18 Suppl. C: C33–9
David D, Segni ED, Klein HO, et al. Inefficacy of digitalis in the control of heart rate in patients with chronic atrial fibrillation: beneficial effect of an added beta adrenergic blocking agent. Am J Cardiol 1979; 44: 1379–82
Lundstrom T, Rydén L. Ventricular rate control and exercise performance in chronic atrial fibrillation: effects of diltiazem and verapamil. J Am Coll Cardiol 1990; 16: 86–90
British National Formulary, number 34. London: British Medical Association and Pharmaceutical Press, 1997 Sep: 546–75
Epstein LM, Chiesa N, Wong MN, et al. Radiofrequency catheter ablation in the treatment of supraventricular tachycardia in the elderly. J Am Coll Cardiol 1994; 23: 1356–62
Crijns HJGM, Van Gelder IC, Tieleman RG, et al. Long-term outcome of electrical cardioversion in patients with chronic atrial flutter. Heart 1997; 77: 56–61
Stambler BS, Wood MA, Ellenbogen KA, the Ibutilide Repeat Dose Study investigators. Efficacy and safety of repeated doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation 1996; 94: 1613–21
American College of Physicians. Guidelines for medical treatment for stroke prevention. Ann Intern Med 1994; 121: 54–5
Howard PA, Duncan PW. Primary stroke prevention in nonvalvular atrial fibrillation: implementing the clinical trial findings. Ann Pharmacother 1997; 31: 1187–96
Rights and permissions
About this article
Cite this article
Supraventricular arrhythmias in the elderly: choose therapy with care. Drugs Ther. Perspect 11, 5–8 (1998). https://doi.org/10.2165/00042310-199811070-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00042310-199811070-00002